KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Working Capital Changes (2017 - 2025)

Historic Other Working Capital Changes for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $10.2 million.

  • Amneal Pharmaceuticals' Other Working Capital Changes rose 26032.2% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year increase of 27441.86%. This contributed to the annual value of $959000.0 for FY2024, which is 10253.61% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Other Working Capital Changes of $10.2 million as of Q3 2025, which was up 26032.2% from $9.5 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Other Working Capital Changes' 5-year high stood at $115.3 million during Q2 2022, with a 5-year trough of -$85.4 million in Q3 2022.
  • Its 5-year average for Other Working Capital Changes is -$241210.5, with a median of -$602000.0 in 2021.
  • The largest annual percentage gain for Amneal Pharmaceuticals' Other Working Capital Changes in the last 5 years was 83471.76% (2022), contrasted with its biggest fall of 253557.77% (2022).
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Other Working Capital Changes stood at -$5.5 million in 2021, then crashed by 703.01% to -$44.3 million in 2022, then surged by 70.62% to -$13.0 million in 2023, then skyrocketed by 91.36% to -$1.1 million in 2024, then surged by 1004.54% to $10.2 million in 2025.
  • Its Other Working Capital Changes stands at $10.2 million for Q3 2025, versus $9.5 million for Q2 2025 and $513000.0 for Q1 2025.